UCB to Present 12 Abstracts on Bimekizumab at AAD VMX 2021 

At UCB, we have come to develop a deep understanding of the patient experience and the unmet needs of people living with immuno-dermatological conditions. As we join for the American Academy of Dermatology VMX 2021 Conference, read from Rhonda Peebles, our Head of U.S. Dermatology, on UCB’s approach to creating value for patients.

• 15 scientific presentations highlight data on BRIVACT^® (brivaracetam) CV, NAYZILAM^® (midazolam) nasal spray CIV, VIMPAT^® (lacosamide) CV, and others, illustrating UCB’s commitment to developing new treatment options for patients in their treatment journey
• UCB’s VIMPAT, recently approved by the U.S. Food and Drug Administration (FDA) as adjunctive therapy in the treatment of primary generalized tonic-clonic seizures (PGTCS), will be highlighted during virtual symposium featuring expert neurology panel

UCB and Stanford Medicine have established a multi-year collaboration to enhance patient value for people living with severe diseases.